Pioneering the future of targeted protein egradation therapeutics d Safe harbor and forward-looking statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995that involve substantial risks and uncertainties, includingstatements regarding the anticipated timing of our planned clinical trials within our pipeline, includingVERITAC-3, atrial of ARV-471 in combination with palbociclib, our ARV-471 monotherapy study in the adjuvant s ...